BUZZ-Wave Life rises after regaining full rights to genetic disorder therapy from GSK

Reuters02-03
BUZZ-<a href="https://laohu8.com/S/WVE">Wave Life</a> rises after regaining full rights to genetic disorder therapy from GSK

** Shares of drug developer Wave Life Sciences WVE.O rise 3.6% to $13.40

** Co says it has regained full rights to WVE-006, its experimental genetic disorder therapy, from GSK GSK.L

** WVE plans to engage with the US FDA on a potential accelerated approval pathway, with regulatory feedback expected mid-2026 for the therapy

** Co is testing the therapy as a potential treatment to alpha-1 antitrypsin deficiency, a genetic disorder that can lead to serious lung and liver diseases due to low levels of the protein alpha-1 antitrypsin

** Data from its ongoing clinical trial testing WVE-006 is on track for Q1 of 2026, co says

** "Decision is due to strategic re-prioritization by partner GSK vs. data driven as no new data were disclosed"- Jefferies

** "We think it makes sense as GSK may be more interested in large indications, such as COPD"- Truist

** WVE rose 37.4% last year

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment